American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Fresenius SE & Co. KGaA (FSNUY)

$12.48 +1.46% OTC: FSNUY · 15-min delayed

Public · OTC: FSNUY
Founded 1981

Visit website Follow

FSNUYOTC

1981Founded

About Fresenius SE & Co. KGaA

FRESENIUS SE S/ADR

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Founded: 1981
Type: Public · OTC: FSNUY
Industry: Medical Devices
Website: Visit site

Registry IDs

Ticker: FSNUY OTC
SEC CIK: 904868
LEI: XDFJ0CYCOO1FXRFTQS51
SIC: 3841 Surgical & Medical Instruments & Apparatus

Embed this company’s badge

Show Fresenius SE & Co. KGaA’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/fresenius-se-co-kgaa/"><img src="https://americancompanies.com/badge/fresenius-se-co-kgaa.svg" alt="Fresenius SE & Co. KGaA — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Fresenius SE & Co. KGaA and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

OTC: FSNUY

$12.48 +1.46%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$10.40 $22.45

52-week range

Dividend yield: 2.44%
Open: —
Day range: –
Prev close: —
Volume: —

Fresenius SE & Co. KGaA (FSNUY) Stock Price

Trading 44% below its 52-week high.
Pays a dividend yielding about 2.44% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Fresenius SE & Co. KGaA.

Write a review

Newsroom

News about Fresenius SE & Co. KGaA

Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies GlobeNewswire Inc. · 2026-07-24 · positive Saudi Arabia Pharmaceutical CDMO Market Research Report 2025 Featuring Tabuk Manufacturing, Lifera, Saudi Bio, Fresenius Kabi, Hikma Pharma, Pfizer, Novartis GlobeNewswire Inc. · 2025-05-13 · positive $9.48 Bn Medical Foods for Inborn Errors of Metabolism Market Opportunities and Strategies to 2034 GlobeNewswire Inc. · 2025-05-09 · positive Infusion Pumps Market to Soar at a CAGR of ~10% by 2032, Owing to the Advancements in Technology and Increased Demand in Healthcare | DelveInsight GlobeNewswire Inc. · 2025-04-17 · positive Global Prefilled Syringes Market to Cross USD 28 Billion by 2032 | DelveInsight GlobeNewswire Inc. · 2025-04-10 · positive Parenteral Nutrition Research Analysis 2024: A Global $13.6 Billion Market by 2029, Driven by Increased Utilization of Premixed PN Formulations and Growing Preference for Home Parenteral Nutrition GlobeNewswire Inc. · 2025-03-24 · positive

News & sentiment via Polygon.io

FAQ

Fresenius SE & Co. KGaA: frequently asked questions

Is Fresenius SE & Co. KGaA an American company?

Fresenius SE & Co. KGaA is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Fresenius SE & Co. KGaA publicly traded?

Yes — Fresenius SE & Co. KGaA is a publicly traded company. Its stock trades under the ticker symbol FSNUY on the OTC.

What does Fresenius SE & Co. KGaA do?

Fresenius SE & Co. KGaA is an American Medical Devices company in the Health & Beauty sector.

When was Fresenius SE & Co. KGaA founded?

Fresenius SE & Co. KGaA was founded in 1981.

Explore